O
OrphoMed
San francisco bay area pharmaceutical company focused on the development of novel
About OrphoMed
OrphoMed is a clinical-stage biotechnology company specializing in the development of advanced treatments for gastrointestinal disorders using its proprietary dimer therapeutics platform. The company primarily targets patients suffering from irritable bowel syndrome with diarrhea (IBS-D), acute and chronic pain, and cystic fibrosis. Operating in the biopharmaceutical market, OrphoMed's business model revolves around the research, development, and commercialization of novel therapeutics. Revenue is generated through funding rounds, partnerships, and eventually, the sale of approved treatments. The company serves a niche market of patients with specific gastrointestinal conditions, aiming to provide best-in-class therapeutic options. Recent activities include securing a $39 million Series A financing round and presenting clinical trial results at various industry forums. OrphoMed's leadership includes experienced professionals like Gary M. Phillips, M.D., and Mark Sostek, M.D., who drive the company's strategic and clinical initiatives.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Mill Valley, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 56.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Intellectual Property, Risk Management, Biotechnology, Neurology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2017 | $39M | $156M | NEA · Takeda Ventures · Relativity Healthcare Partners · Takeda | — |
| DEBT✓Debt | Jan 2016 | $2.8M | — | Takeda Ventures | — |
Growth signals
Latest recorded traffic for OrphoMed is 380 monthly website visits, up 192.3% over the last three months. OrphoMed's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
NEA
Takeda
Relativity Healthcare Partners
Pappas Capital
Series B and later1 investor entered at this stage
Takeda Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about OrphoMed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OrphoMed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.